Cite
HARVARD Citation
Nishikawa, M. et al. (2021). CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma. Cancer medicine. pp. 2013-2025. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Nishikawa, M. et al. (2021). CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma. Cancer medicine. pp. 2013-2025. [Online].